Product Pipeline

NASH, ASH, Diabetes, C-Diff,  Colitis and UPEC.


The company, using its proprietary technology, initiated the following R&D path for multiple applications:

  1. Nonalcoholic Steatohepatitis (NASH): based on its previous clinical data the company initiated - A Phase II, multicenter, double blind Randomized clinical study in the USA, Australia and Israel. The study's goal is to assess the safety and effectiveness of IMM-124E for the treatment of NASH.  A total of 120 NASH patients are now enrolled in the study, comparing 2 doses of IMM-124E to placebo for a 6 months period. The study design had been reviewed by the FDA and finalized under the agencies recommendation. Study is expected to end by the end of H2 2017.

  2. Alcoholic SteatoHepatits (ASH): Immuron's platform had been identified and chosen by the leading research group within the NIH to have the potential to treat this disease, which is of high importance currently. The NASH CRN, led by the former president of the AASLD, prof. Arun Sanyal, is currently conducting a randomized placebo control study on 66 ASH patients in the USA. The study is expected to generate safety as well as preliminary efficacy data and should be completed by the end of 2016.

  3. Diabetes: based on previous phase 1 clinical data, the company decided to move forward and develop a phase 2 study protocol to submit to the FDA intended for a New Drug Application (NDA).

  4. Clostridium Difficile (C-Diff): Immuron joined hands with the Monash University in Melbourne to develop a unique product - the IMM-529 - for prevention and treatment of C-diff. infections. The collaboration has generated promising data and the company is planning to maintain the support to reach clinical phased trials.

  5. Colitis: Immuron conducted animal studies with a variety of Colitis models and is moving forward with leading key opinion leaders to continue development. 

  6. Uropathogenic Escherichia Coli (UPEC): Pre Clinical work has begun at Monash University using a novel Hyper immune anti UPEC product produced by Immuron to treat one of the most common diseases,  Urinary Tract Infections.